Prevention by calcium administration of reserpine action on rat brain noradrenaline stores: a reappraisal

L. Manara, C. Cerletti, T. Mennini

Research output: Contribution to journalArticle

Abstract

The conditions under which pretreatment with a calcium salt may prevent the action of reserpine on brain noradrenaline stores in the rat were investigated. The results show that only after subcutaneous administration of reserpine in the same site as a previous CaCl2 injection, was the action of reserpine prevented and reduced levels of this drug were found in the brain. Conversely, the depletion of encephalic noradrenaline following reserpine, as well as the reserpine brain concentration, were not affected by subcutaneously administered calcium chloride, when reserpine was administered either intravenously, or subcutaneously in a site different from that selected for pretreatment with the calcium salt. In essence calcium chloride, a well known irritant, acts accordingly at the site of subcutaneous administration, thus limiting by a non specific mechanism the absorption of reserpine. Under similar conditions, in fact, the absorption of a different drug, i.e. harmaline, was likewise altered. In view of these findings the significance of some studies on calcium reserpine interaction appearing in the literature requires a reappraisal.

Original languageEnglish
Pages (from-to)471-487
Number of pages17
JournalResearch Communications in Chemical Pathology and Pharmacology
Volume14
Issue number3
Publication statusPublished - 1976

Fingerprint

Reserpine
Rats
Brain
Norepinephrine
Calcium
Calcium Chloride
Salts
Harmaline
Irritants
Pharmaceutical Preparations
Injections

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

@article{6d5ac6e90be34149bb2f0def5575a542,
title = "Prevention by calcium administration of reserpine action on rat brain noradrenaline stores: a reappraisal",
abstract = "The conditions under which pretreatment with a calcium salt may prevent the action of reserpine on brain noradrenaline stores in the rat were investigated. The results show that only after subcutaneous administration of reserpine in the same site as a previous CaCl2 injection, was the action of reserpine prevented and reduced levels of this drug were found in the brain. Conversely, the depletion of encephalic noradrenaline following reserpine, as well as the reserpine brain concentration, were not affected by subcutaneously administered calcium chloride, when reserpine was administered either intravenously, or subcutaneously in a site different from that selected for pretreatment with the calcium salt. In essence calcium chloride, a well known irritant, acts accordingly at the site of subcutaneous administration, thus limiting by a non specific mechanism the absorption of reserpine. Under similar conditions, in fact, the absorption of a different drug, i.e. harmaline, was likewise altered. In view of these findings the significance of some studies on calcium reserpine interaction appearing in the literature requires a reappraisal.",
author = "L. Manara and C. Cerletti and T. Mennini",
year = "1976",
language = "English",
volume = "14",
pages = "471--487",
journal = "Research Communications in Molecular Pathology and Pharmacology",
issn = "0034-5164",
publisher = "PJD Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Prevention by calcium administration of reserpine action on rat brain noradrenaline stores

T2 - a reappraisal

AU - Manara, L.

AU - Cerletti, C.

AU - Mennini, T.

PY - 1976

Y1 - 1976

N2 - The conditions under which pretreatment with a calcium salt may prevent the action of reserpine on brain noradrenaline stores in the rat were investigated. The results show that only after subcutaneous administration of reserpine in the same site as a previous CaCl2 injection, was the action of reserpine prevented and reduced levels of this drug were found in the brain. Conversely, the depletion of encephalic noradrenaline following reserpine, as well as the reserpine brain concentration, were not affected by subcutaneously administered calcium chloride, when reserpine was administered either intravenously, or subcutaneously in a site different from that selected for pretreatment with the calcium salt. In essence calcium chloride, a well known irritant, acts accordingly at the site of subcutaneous administration, thus limiting by a non specific mechanism the absorption of reserpine. Under similar conditions, in fact, the absorption of a different drug, i.e. harmaline, was likewise altered. In view of these findings the significance of some studies on calcium reserpine interaction appearing in the literature requires a reappraisal.

AB - The conditions under which pretreatment with a calcium salt may prevent the action of reserpine on brain noradrenaline stores in the rat were investigated. The results show that only after subcutaneous administration of reserpine in the same site as a previous CaCl2 injection, was the action of reserpine prevented and reduced levels of this drug were found in the brain. Conversely, the depletion of encephalic noradrenaline following reserpine, as well as the reserpine brain concentration, were not affected by subcutaneously administered calcium chloride, when reserpine was administered either intravenously, or subcutaneously in a site different from that selected for pretreatment with the calcium salt. In essence calcium chloride, a well known irritant, acts accordingly at the site of subcutaneous administration, thus limiting by a non specific mechanism the absorption of reserpine. Under similar conditions, in fact, the absorption of a different drug, i.e. harmaline, was likewise altered. In view of these findings the significance of some studies on calcium reserpine interaction appearing in the literature requires a reappraisal.

UR - http://www.scopus.com/inward/record.url?scp=0017126718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017126718&partnerID=8YFLogxK

M3 - Article

C2 - 959653

AN - SCOPUS:0017126718

VL - 14

SP - 471

EP - 487

JO - Research Communications in Molecular Pathology and Pharmacology

JF - Research Communications in Molecular Pathology and Pharmacology

SN - 0034-5164

IS - 3

ER -